BioCentury
ARTICLE | Clinical News

Viscogel: Phase I/II started

April 30, 2012 7:00 AM UTC

Viscogel began a single-blind Phase I/II trial of ViscoGel in about 130 healthy volunteers. The Phase I portion will evaluate single ascending-doses of ViscoGel as an adjuvant in about 30 volunteers. The Phase II portion will compare the dose selected from the first portion in combination with 0.2 and 2 µg ActHIB Hib vaccine vs. 0.2, 2 and 10 µg ActHIB alone. Sanofi (Euronext:SAN; NYSE:SNY, Paris, France) markets ActHIB. ...